EP2558486A1 - Construction antigenique et ses applications pour le depistage de trypanosomoses chez l'homme et l'animal - Google Patents
Construction antigenique et ses applications pour le depistage de trypanosomoses chez l'homme et l'animalInfo
- Publication number
- EP2558486A1 EP2558486A1 EP11720188A EP11720188A EP2558486A1 EP 2558486 A1 EP2558486 A1 EP 2558486A1 EP 11720188 A EP11720188 A EP 11720188A EP 11720188 A EP11720188 A EP 11720188A EP 2558486 A1 EP2558486 A1 EP 2558486A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antigenic construct
- screening
- antigenic
- animal
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
Definitions
- the subject of the invention is an antigenic construct and its use for developing a kit and implementing a method for trypanosomosis screening in humans and animals.
- HAT Human African trypanosomiasis
- AAT animal trypanosomiasis
- stage 1 lymphatic-blood
- stage 2 neurological
- melarsoprol whose toxic side effects are important (overall mortality of 5-10% ).
- stage 1 lymphatic-blood
- stage 2 neurological
- the diagnosis of stage still depends today on the examination of the cerebrospinal fluid after lumbar puncture and the positivity threshold of the cytorachia is still debated (5, 10 or 20 cells / ⁇ ).
- CATT Card Agglutination Test For Trypanosomiasis
- the assay includes fixed trypanosomes of LiTat variant 1.3.
- a variant of CATT consists of semi-purified antigens (LiTat 1.3, 1.5 and 1.6) coupled to latex beads.
- the main problem related to CATT is a lack of specificity because the antigens used are responsible for many cross-reactions and thus false positives.
- blood, diluted blood or plasma have variable antibody titers against these antigens. Thus parasito logically positive patients may be CATT negative.
- the CATT does not allow the diagnosis of stage and a satisfactory serological follow-up of the patients after treatment, in particular because of the cross reactions with other infections.
- High titers of anti-WE antibodies of IgM isotype were measured by ELISA in the serum of patients with human African trypanosomiasis (HAT), and increased titers were found in stage 2 patients (Okomo-Assoumou et al. al., 1995 (ref 2)).
- the work of the inventors in this field has shown an unexpected effect of glutaraldehyde on the optimal orientation that it confers on synthetic antigen. Indeed, it has been found that glutaraldehyde serves as a spacer and orienting arm of the synthetic antigen WE when it is coupled to an inert support such as latex beads or ELISA plates. As illustrated in FIGS. 1A and 1B, to which the following example refers, the antigenic construct of the invention constitutes a mimotope of the natural antigen, when it is coupled only to the latter, which allows better recognition by anti-WE antibodies.
- the object of the invention is therefore to provide a new antigenic construct. It also aims to take advantage of the properties of this construction in a kit and a screening method for human and animal trypanosomoses.
- the antigenic construct of the invention is based on the coupling of an epitope of interest to glutaraldehyde and their attachment to an inert carrier.
- the invention thus relates to an antigenic construct containing a tryptophan epitope, characterized in that it is formed of a tryptophan motif W, or a peptide of 3 or 4 amino acids comprising a motif W, coupled with glutaraldehyde.
- said peptide corresponds to the sequence SEQ ID No. 1 CxWy, in which "x” represents K, A, S, V, T, R, I, E, D, N or G, and "y” represents D, S, T, E, N, K, G, Q, R or I, either of "x” or "y” may be absent.
- a representative sequence, SEQ ID No. 2, is of the CKWD type.
- said coupling product is grafted onto latex beads. This formulation makes it possible to develop a rapid agglutination technique on the sera of patients or animals affected, respectively, with THA or TAA.
- the coupling product is grafted onto ELISA plates, making it possible to develop a quantitative technique of "anti-trypanosome" antibody levels in patients or animals suffering from HAT or TAA.
- the coupling product as defined above is grafted onto poly-L-lysine deposited at the bottom of ELISA plates.
- This arrangement makes it possible to have a completely synthetic system, whether for the development in the form of beads or ELISA test.
- the invention also relates to a screening kit for THA or TAA, characterized in that it comprises
- one or more reagents for the antigen / antibody reaction and / or buffer solutions and / or reagents for the detection, quantification or visualization of antigen / antibody complexes when present are one or more reagents for the antigen / antibody reaction and / or buffer solutions and / or reagents for the detection, quantification or visualization of antigen / antibody complexes when present.
- the kit above advantageously comprises, according to a further feature of the invention, the reagents for carrying out an immunoassay, especially an indirect ELISA or an ELISA inhibition test, making an anti-monoclonal antibody compete with one another. -WE with anti-WE antibodies infected host sera.
- the antigenic construct is attached to a support.
- the invention is further directed to a method for screening for THA or TAA, characterized in that it comprises
- This new serological diagnostic test which is cheap, stable and easy to handle, combined with an indirect ELISA or an ELISA-based inhibition test based on anti-WE antibodies and which has proved its effectiveness, can be used for a diagnosis of mass and stage (determination of antibody titers of patients in stages 1 and 2) of HAT or TAA in the field, with high specificity.
- This test is particularly suitable for a specific screening of human or animal African trypanosomiasis.
- FIGS. 1 to 5 represent, respectively,
- Figures 1A-1C the native steric hindrance of the CKWD sequence (Figure 1A), an inert carrier-type sequence with amine-glutaraldehyde-W function ( Figure 1B), and a sequence attached to an ELISA plate (Fig. . 1 C)
- Figure 2 and 3 the diagnostic test results, respectively, on human serum and blood
- Figure 4 a graph of results obtained with animal sera infected with different species of Trypanosomes
- Example 1 synthesis of coupling products W-glutaraldehyde or C-x-W-y-glutaraldehyde Production of coupled latex beads
- hapten tryptophan or peptide
- concentration of 5 mg / ml in a 1.5 M acetate buffer, pH 8.3, vial 100 ⁇ l of 5% glutaraldehyde are added under vortex for approximately 10 seconds.
- amino latex beads (Sigma) are added and allowed to react for at least 10 minutes with slow stirring.
- the reaction is stopped by addition of 100 ⁇ l of 1M NaBH 4 and leave the mixture for 10 minutes while stirring slowly.
- the mixture is dialyzed against distilled water supplemented with NaBH 4 (lspatula / 51) all day long by changing the dialysis water 2 to 3 times, then about 14h (all night) with water, remove the excess of NaBH 4 .
- FIGS. 1A and 1B show the planarized chemical formulas of the native epitopic sequence and the chemical sequences used according to the invention which clearly show that the construction of the invention reproduces the molecular configuration of the epitope of the invention. 'interest.
- ELISA plate (Nunc, PolySorp or MaxiSorp)
- 200 ⁇ l of a mixture of ⁇ of hapten tryptophan or peptide, 5 mg / ml in a 1.5 M acetate buffer pH 8.3 are added.
- 100 ⁇ l of 5% glutaraldehyde added under vortex for about 10 seconds. Allowed to react for at least 30 minutes with slow stirring.
- reaction is stopped by the addition of 100 ⁇ l of 1M NaBH 4 and the mixture is left for 10 minutes while stirring slowly.
- the plates are washed (5 times 1 hour) with distilled water containing NaBH 4 (lspatule / 51), then about 14 hours (overnight) with water only, to remove excess NaBH 4 .
- Example 3 Diagnostic Test Associating an ELISA Test for the Diagnosis of Stage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1052784A FR2958753B1 (fr) | 2010-04-13 | 2010-04-13 | Construction antigenique et ses applications pour le depistage de trypanosomoses chez l'homme et l'animal |
PCT/IB2011/051605 WO2011128863A1 (fr) | 2010-04-13 | 2011-04-13 | Construction antigenique et ses applications pour le depistage de trypanosomoses chez l'homme et l'animal |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2558486A1 true EP2558486A1 (fr) | 2013-02-20 |
Family
ID=43127332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11720188A Withdrawn EP2558486A1 (fr) | 2010-04-13 | 2011-04-13 | Construction antigenique et ses applications pour le depistage de trypanosomoses chez l'homme et l'animal |
Country Status (5)
Country | Link |
---|---|
US (1) | US9201070B2 (fr) |
EP (1) | EP2558486A1 (fr) |
AP (1) | AP4006A (fr) |
FR (1) | FR2958753B1 (fr) |
WO (1) | WO2011128863A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3036287A1 (fr) * | 2015-05-19 | 2016-11-25 | Univ Bordeaux | Traitement et detection des trypanosomes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997018475A1 (fr) * | 1995-11-14 | 1997-05-22 | Corixa Corporation | Composes et procedes de detection et de prevention d'infections par t. cruzi |
WO2003068801A2 (fr) * | 2002-02-11 | 2003-08-21 | Genentech, Inc. | Variantes d'anticorps a vitesses d'association d'antigene accelerees |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
US6133445A (en) * | 1997-12-17 | 2000-10-17 | Carnegie Mellon University | Rigidized trimethine cyanine dyes |
US7205275B2 (en) * | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
-
2010
- 2010-04-13 FR FR1052784A patent/FR2958753B1/fr active Active
-
2011
- 2011-04-13 WO PCT/IB2011/051605 patent/WO2011128863A1/fr active Application Filing
- 2011-04-13 US US13/640,523 patent/US9201070B2/en not_active Expired - Fee Related
- 2011-04-13 AP AP2012006557A patent/AP4006A/en active
- 2011-04-13 EP EP11720188A patent/EP2558486A1/fr not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997018475A1 (fr) * | 1995-11-14 | 1997-05-22 | Corixa Corporation | Composes et procedes de detection et de prevention d'infections par t. cruzi |
WO2003068801A2 (fr) * | 2002-02-11 | 2003-08-21 | Genentech, Inc. | Variantes d'anticorps a vitesses d'association d'antigene accelerees |
US20030224397A1 (en) * | 2002-02-11 | 2003-12-04 | Genentech, Inc. | Antibody variants with faster antigen association rates |
Non-Patent Citations (4)
Title |
---|
OKOMO-ASSOUMOU M C ET AL: "Circulating antibodies directed against tryptophan-like epitopes in sera of patients with human African trypanosomiasis", AMERICAN JOURNAL OF TROPICAL MEDICINE & HYGIENE, AMERICAN SOCIETY OF TROPICAL MEDICINE AND HYGIENE, US, vol. 52, no. 5, 1 January 1995 (1995-01-01), pages 461 - 467, XP008129963, ISSN: 0002-9637 * |
See also references of WO2011128863A1 * |
SEMBALLA ET AL: "Identification of a tryptophan-like epitope borne by the variable surface glycoprotein (VSG) of African trypanosomes", EXPERIMENTAL PARASITOLOGY, NEW YORK, NY, US, vol. 115, no. 2, 29 November 2006 (2006-11-29), pages 173 - 180, XP005727696, ISSN: 0014-4894, DOI: 10.1016/J.EXPPARA.2006.08.008 * |
VINCENDEAU P ET AL: "Importance of L-tryptophan metabolism in trypanosomiasis", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRINGER, US, vol. 467, 1 January 1999 (1999-01-01), pages 525 - 531, XP008130027, ISSN: 0065-2598 * |
Also Published As
Publication number | Publication date |
---|---|
FR2958753A1 (fr) | 2011-10-14 |
FR2958753B1 (fr) | 2018-03-16 |
WO2011128863A1 (fr) | 2011-10-20 |
US20130203085A1 (en) | 2013-08-08 |
AP2012006557A0 (en) | 2012-12-31 |
US9201070B2 (en) | 2015-12-01 |
AP4006A (en) | 2017-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0311492B1 (fr) | Trousse et méthode de dosage immunométrique applicables à des cellules entières | |
CA2721049C (fr) | Procede de diagnostic d'une hypertension arterielle pulmonaire | |
EP2470907B1 (fr) | Proteines utilisees pour le diagnostic d'une borreliose de lyme | |
EP2558486A1 (fr) | Construction antigenique et ses applications pour le depistage de trypanosomoses chez l'homme et l'animal | |
WO1999009414A1 (fr) | Utilisation de proteines d'enveloppe recombinantes pour le diagnostic du virus de la dengue | |
FR2709492A1 (fr) | Méthode d'immunodosage spécifique de la glutathion peroxydase plasmatique humaine, kit pour sa mise en Óoeuvre, oligopeptides et anticorps spécifiques de la méthode . | |
FR2640143A1 (fr) | Anticorps polymerises, diriges contre des immunoglobulines - leur utilisation dans des tests de diagnostic | |
WO1989001045A1 (fr) | Antigenes specifiques de leishmania et leur procede de preparation, profils antigeniques contenant ces antigenes et leur application au diagnostic des leishmanioses viscerales | |
EP0165830A1 (fr) | Anticorps monoclonaux anticytomégalovirus et procédés pour le diagnostic in vitro des infections par les cytomégalovirus humains et d'une protéine-kinase inductible par les cytomégalovirus et susceptible d'être reconnue par les susdits anticorps monoclonaux | |
EP0623145A1 (fr) | Peptides du caseinomacropeptide, anticorps contre lesdits peptides et utilisations. | |
WO2022036337A1 (fr) | Compositions et méthodes pour un polypeptide recombinant imitant la protéine nucléocapside (np) du sars-cov-2 | |
FR3062919A1 (fr) | Methode de dosage immunologique d'anticorps specifiques d'antigenes de virus de la famille des poxviridae | |
EP2470908B1 (fr) | Proteines utilisees pour le diagnostic d'une borreliose de lyme | |
EP1804061A1 (fr) | Utilisation de la protéine 5E2 dans le diagnostic in vitro d'infections à Legionella pneumophila | |
EP2909630A1 (fr) | Antigenes gra recombinants et leur application pour le diagnostic precoce de la toxoplasmose | |
WO2010128232A2 (fr) | Méthode de diagnostic des infections à propionibacterium acnes | |
EP2558485B1 (fr) | Antigènes polypeptidiques de trichinella, et leurs applications | |
FR3109446A1 (fr) | Detection immunologique du sars-cov2 dans un echantillon salivaire | |
FR2945291A1 (fr) | Anticorps biomarqueur et dispositif de diagnostic pour la detection de certaines maladies auto-immunes | |
EP0122833A1 (fr) | Procédé de dosage en phase hétérogène de substances biologiques antigéniques, mettant en oeuvre des conjugués hybrides d'anticorps et réactifs pour sa mise en oeuvre | |
EP0292404A1 (fr) | Test de diagnostic du SIDA basé sur la mise en évidence d'une diversité de la réponse isotypique | |
EP0238396A1 (fr) | Produit d'immuno-essai, son procédé de préparation, son utilisation, complexe immunogène le comportant et utilisation de ce complexe | |
FR2930646A1 (fr) | Detection, in vitro, d'anticorps produits a la suite d'une infection a legionella pneumophila | |
WO1998029450A1 (fr) | Peptides antigeniques reagissant avec les anticorps anti-ovaire | |
FR2698694A1 (fr) | Moyens pour la détection in vitro d'IgE dirigées contre un nouvel allergène d'insectes lépidoptères: la thaumétopoéine. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121023 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD) Owner name: CENTRE DE COOPERATION INTERNATIONALE EN RECHERCHE |
|
17Q | First examination report despatched |
Effective date: 20151001 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20171219 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20181101 |